Repurposing ibudilast to mitigate Alzheimer’s disease by targeting inflammation
Brain · 2023
DOI: 10.1093/brain/awac136 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain, 2023. Verfasst von Giovanni Oliveros und 8 weiteren Autor:innen. Beteiligte Einrichtung: Program in Biochemistry, The Graduate Center, CUNY, 365 5th Ave, New York, NY 10016, USA. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIGMS NIH HHS, NIGMS.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer’s disease is a multifactorial disease that exhibits cognitive deficits, neuronal loss, amyloid plaques, neurofibrillary tangles and neuroinflammation in the brain. Hence, a multi-target drug would improve treatment efficacy. We applied a new multi-scale predictive modelling framework that integrates machine learning with biophysics and systems pharmacology to screen drugs for Alzheimer’s disease using patients’ tissue samples. Our predictive modelling framework identified ibudilast as a drug with repurposing potential to treat Alzheimer’s disease. Ibudilast is a multi-target drug, as it is a phosphodiesterase inhibitor and toll-like receptor 4 (TLR4) antagonist. In addition, we predict that ibudilast inhibits off-target kinases (e.g. IRAK1 and GSG2). In Japan and other Asian countries, ibudilast is approved for treating asthma and stroke due to its anti-inflammatory potential. Based on these previous studies and on our predictions, we tested for the first time the efficacy of ibudilast in Fisher transgenic 344-AD rats. This transgenic rat model is unique as it exhibits hippocampal-dependent spatial learning and memory deficits and Alzheimer’s disease pathology, including hippocampal amyloid plaques, tau paired-helical filaments, neuronal loss and microgliosis, in a progressive age-dependent manner that mimics the pathology observed in Alzheimer’s disease patients. Following long-term treatment with ibudilast, transgenic rats were evaluated at 11 months of age for spatial memory performance and Alzheimer’s disease pathology. We demonstrate that ibudilast-treatment of transgenic rats mitigated hippocampal-dependent spatial memory deficits, as well as hippocampal (hilar subregion) amyloid plaque and tau paired-helical filament load, and microgliosis compared to untreated transgenic rat. Neuronal density analysed across all hippocampal regions was similar in ibudilast-treated transgenic compared to untreated transgenic rats. Interestingly, RNA sequencing analysis of hippocampal tissue showed that ibudilast-treatment affects gene expression levels of the TLR and ubiquitin-proteasome pathways differentially in male and female transgenic rats. Based on the TLR4 signalling pathway, our RNA sequencing data suggest that ibudilast-treatment inhibits IRAK1 activity by increasing expression of its negative regulator IRAK3, and/or by altering TRAF6 and other TLR-related ubiquitin ligase and conjugase levels. Our results support that ibudilast can serve as a repurposed drug that targets multiple pathways including TLR signalling and the ubiquitin/proteasome pathway to reduce cognitive deficits and pathology relevant to Alzheimer’s disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Program in Biochemistry, The Graduate Center, CUNY, 365 5th Ave, New York, NY 10016, USA.
- Department of Biological Sciences, Hunter College, 695 Park Ave, New York, NY 10065, USA.
- Department of Computer Science, Hunter College, 695 Park Ave, New York, NY 10065, USA.
- Program in Biology, The Graduate Center, CUNY, 365 5th Ave, New York, NY 10016, USA.
- Program in Computer Science and Biochemistry, The Graduate Center, 365 5th Ave, New York NY 10016, USA.
- Helen and Robert Appel Alzheimer's disease Research Institute, Feil Family Brain & Mind Research Institute, Weill Cornell Medicine, Cornell University, 411 E 69th St, New York, NY 10021, USA.
ORCID-Profile: Yue Qiu, Peter A Serrano
Förderung
- NIA NIH HHS
- NIGMS NIH HHS
- NIGMS
- NIA
- City University of New York
- NIH
Zitieren
APA
Oliveros, G., Wallace, C. H., Chaudry, O., Liu, Q., Qiu, Y., Xie, L., Rockwell, P., Figueiredo-Pereira, M. E., & Serrano, P. A. (2023). Repurposing ibudilast to mitigate Alzheimer’s disease by targeting inflammation. Brain. https://doi.org/10.1093/brain/awac136
Vancouver
Oliveros G, Wallace CH, Chaudry O, Liu Q, Qiu Y, Xie L, et al. Repurposing ibudilast to mitigate Alzheimer’s disease by targeting inflammation. Brain. 2023. doi:10.1093/brain/awac136
BibTeX
@article{Oliveros2023,
author = {Oliveros, Giovanni and Wallace, Charles H and Chaudry, Osama and Liu, Qiao and Qiu, Yue and Xie, Lei and Rockwell, Patricia and Figueiredo-Pereira, Maria E and Serrano, Peter A},
title = {Repurposing ibudilast to mitigate Alzheimer’s disease by targeting inflammation},
journal = {Brain},
year = {2023},
doi = {10.1093/brain/awac136}
}
EUVIMED